Back to Journal

Journal of Surgical Oncology & Clinical Research

Percentage of Surgical Lung Cancers Missed by National Screening Criteria

[ ISSN : 3068-0727 ]

Abstract Citation Introduction Materials and Methods Results Discussion Acknowledgements References
Details

Received: 15-Aug-2017

Accepted: 12-Sep-2017

Published: 22-Sep-2017

Hannah A Lee¹, Asa Dewan MS², Kelly Rubino BSN³, Mila Lachica BA¹,², Arthur A Topilow⁴ and Thomas L Bauer³*

¹Axelrod Research Group, Jersey Shore University Medical Center, USA
²Office of Research Administration, Jersey Shore University Medical Center, USA
³Department of Surgery, Jersey Shore University Medical Center, USA
?Meridian Cancer Care/Research, Jersey Shore University Medical Center, USA

Corresponding Author:

Hannah A. Lee, Axelrod Research Group, Jersey Shore University Medical Center, Neptune, NJ, USA, Tel: (732) 865-5967; Email: hannlee@sas.upenn.edu

Keywords

Lung cancer; Screening; Criteria

Abstract

Background: The US Preventive Services Task Force (USPSTF) recommends screening for smokers based on age, pack-years of smoking, and years since past smokers quit (quit-time). Previous studies determined low dose computerized tomography (LDCT) to be the best method, but have not identified the population at highest risk. This study sought the percentage of lung cancer patients that would have been excluded by USPSTF criteria.

Method: A retrospective chart review identified 170past and present smokers who had undergone lung cancer resection at Hackensack Meridian Health (HMH) hospitals between September 15, 2014 and 2016. Data was collected from the Society of Thoracic Surgeons database. Descriptive statistics and Wilcoxon Rank-Sum tests were used to analyze differences between included and excluded patients.

Results: The percentage of patients that would have been excluded by screening criteria was 46.5% (95% CI: 38.8-54.3%). The difference between ages of included and excluded patients was not quite significant (p=0.051), with only17.1% (95% CI: 11.7-23.6%) of all patients excluded by age. Pack-years of included patients were significantly higher than of the excluded (p<0.001), and 25.3% (95% CI: 18.9-32.6%) had insufficient pack years. Quit-time was also a significant variable (p<0.001) and excluded 37.9% (95% CI: 29.1-49.4%) of past smokers. The percentage included by USPSTF criteria increased from 53.5% to 59.4% when quit-time was set to 25 years, and61.2% when extended to 30 years.

Conclusion: USPSTF criteria would have excluded almost half of the ever-smokers with surgically resectable lung cancers. Age would not have excluded a significant percentage, but inclusion criteria should account for smokers with less than 30 pack-years or who quit over 15 years ago. Future reviews should examine screening efficacy in larger databases. Prospective studies should investigate correlation between age and smoking history, and look to include secondhand smoking and occupational exposure as risk factors for screening.

Citation

Lee HA, Dewan AMS, Rubino KBSN, Lachica MBA, Topilow AA and Bauer TL. Percentage of Surgical Lung Cancers Missed by National Screening Criteria. J Surg Oncol Clin Res. 2017; 1(1): 1003.

Introduction

Lung cancer causes more deaths than any other cancer in the United States. Eighty percent of these deaths can be attributed to smoking, and over half of all lung cancers are diagnosed after 70 years of age [1]. When diagnosed at an early stage, primary cancers can be resected, resulting in a higher chance of survival.

In order to detect lung cancer, past screening utilized Chest X-rays (CXR) and sputum cytology [2]. In 1992, the International Early Lung Cancer Action Program (I-ELCAP) was founded to compare the detection rates of chest radiography and Low-Dose CT (LDCT) [3]. The New York ELCAP screened 1,000 males and females over 60 years old who smoked for at least10 pack-years the number of cigarette packs per day times the number of years smoked and found LDCT to be more effective than CXR because it detected more malignant tumors (2.7% vs 0.7%) and non metastatic cancers (96.3% vs 57.1%) [4]. Follow-up cohorts at the Mayo Clinic and European Institute of Oncology screened individuals of 50 years or older and with at least 20 pack-years of smoking history [5,6]. Other sites screened smokers starting from 45, 50, and 55 years old with at least 10 pack-years, since I-ELCAP allowed sites to determine enrollment eligibility [7-9].

In 2011, the National Lung Screening Trial (NLST) randomly assigned subjects to be screened by either CXR or LDCT, and found that lung cancer mortality decreased by 20.0% when using LDCT instead of CXR [10]. The study enrolled male and female smokers between 55 and 74 years of age who smoked at least 30 pack-years of smoking [10]. Subjects must have been current smokers, or ceased within the past 15 years.

All past trials determined LDCT to be the most effective screening technique, but the population at highest risk has not yet been determined. Based on NLST findings, the US Preventive Services Task Force (USPSTF) currently recommends LDCT screening of adults between 55 and 80 years of age, with at least a 30 pack-year smoking history, and who are current smokers or had quit within the past 15 years [11].

Since lung cancer victims encompass a range of ages and smoking history, USPSTF guidelines may fail to include many cancers that can be surgically removed. In a 2015 cohort study, Yang et al. followed the proportion of lung cancer patients that met USPSTF criteria from 1984 to 2011 [12]. The trends showed a steady decrease in patients who would have met screening guidelines, but separate variables (age, pack-years, and quit-years) were not closely examined [12]. In a follow-up study, Yang et al. suggested that USPSTF criteria include past smokers who had stopped smoking for 15-30 years [13]. However, the results may be inaccurate since nonsmokers were included even though they would have been ineligible for screening, and current smokers were included in the quit-time analysis, despite not quitting [12,13]. The purpose of this study was to determine the percentage of surgical lung cancer patients who have smoked, but would have been excluded by USPSTF guidelines. If this percentage is significant, we would make suggestions so that more surgically resectable cases could be detected by lung cancer screening scans.

Materials and Methods

This was an Institutional Review Board approved, retrospective chart review of surgical lung cancer cases at the Jersey Shore University Medical Center, Riverview Medical Center, Ocean Medical Center, and Bayshore Community Hospital of Hackensack Meridian Health (HMH).Data for lung cancer resections on past and present smokers between September 15, 2014 and September 15, 2016 were collected from the Society of Thoracic Surgeons (STS) database. Patients with insufficient smoking information or who had never smoked were omitted, since they could not be categorized by USPSTF guidelines. Variables analyzed were age, gender, race, tumor stage, cancer type, and smoking history in pack-years and time since smoking ceased (quit-time) of 170 patients. Many variables affect one’s risk for lung cancer but only age (55-80 years), pack-years (≥30), and quit-time (≤15 years)were used to determine inclusion or exclusion by USPSTF guidelines.

Summary statistics were calculated for all study measures including frequency and percentage for categorical variables in addition to range, mean, standard deviation, median, and interquartile range for continuous variables. Exact two-sided 95% confidence intervals were calculated for percentages. Categorical variables were compared between group susing Chi-squaredor Fisher’s exact tests, dependent on expected cell counts. Continuous measures were checked for normality using the Shapiro-Wilk test and then compared between groups using two-sided independent t-tests or Wilcoxon rank-sum tests depending on the result. Ordinal variables were compared between groups using the Wilcoxon rank-sum test. All tests were performed at the 0.05 level of significance.

Inclusion criteria for age, pack-years, and quit-time were individually studied to determine how many cases would have been excluded by each variable alone. Significant percentages of cases that would have been excluded by USPSTF recommendation would prompt further analysis to determine criteria that better includes those at high risk for lung cancer.

Results

Of the 170 cases reviewed, 46.5% (95% CI: 38.8-54.3%) would have been excluded by USPSTF-recommended inclusion criteria for lung screening. In both included and excluded groups, most patients were female and almost all were Caucasian. Overall clinical and pathological staging categorized about 70% of tumors in Stage I. Histologically, cases excluded by USPSTF guidelines were mostly adenocarcinomas and neuroendocrine tumors, while there were more squamous cell carcinomas among the included patients (p<0.001).

The ages of surgery in the chart review ranged from 43 to 87 years old, but only those between 55 and 80 inclusive, would have been screened by USPSTF criteria. Overall, the difference between the age distributions was not statistically significant (Table 1). Criteria for smoking history were specified in pack-years and quit-time, or years since past smokers quit. Excluded patients smoked between 0.8 and 120 pack-years, while the included group’s range was 30 to 160 pack-years. The USPSTF guideline for quit-time only applies to past smokers.

Table 1: Descriptive Statistics of Meridian STS Patients Excluded (n=79) and Included (n=91) by USPSTF Criteria.

 

Excluded, n (%)

Included, n (%)

Gender

Male

34

(43.0%)

38

(41.8%)

 

Female

45

(57.0%)

53

(58.2%)

Age

<50

3

(3.8%)

0

(0.0%)

 

50-54

11

(13.9%)

0

(0.0%)

 

55-59

3

(3.8%)

16

(17.6%)

 

60-64

6

(7.6%)

21

(23.1%)

 

65-69

11

(13.9%)

13

(14.3%)

 

70-74

12

(15.2%)

20

(22.0%)

 

75-80

18

(22.8%)

21

(23.1%)

 

>80

15

(19.0%)

0

(0.0%)

Race

Asian

1

(1.3%)

0

(0.0%)

 

Black

1

(1.3%)

1

(1.1%)

 

Caucasian

77

(97.5%)

89

(97.8%)

 

Other

0

(0.0%)

1

(1.1%)

Smoking History

Smoking Status

Past Smoker

16

(20.3%)

37

(40.7%)

 

Present Smoker

63

(79.7%)

54

(59.3%)

Pack-years

0-29

42

(53.2%)

0

(0.0%)

 

30-59

28

(35.4%)

61

(67.0%)

 

60-89

4

(5.1%)

16

(17.6%)

 

90-119

0

(0.0%)

10

(11.0%)

 

≥120

1

(1.3%)

4

(4.4%)

 

n/a

4

(5.1%)

0

(0.0%)

Quit-time

0-9

30

(38.0%)

77

(84.6%)

 

10-19

7

(8.9%)

14

(15.4%)

 

20-29

20

(25.3%)

0

(0.0%)

 

30-39

10

(12.7%)

0

(0.0%)

 

40-49

7

(8.9%)

0

(0.0%)

 

≥50

4

(5.1%)

0

(0.0%)

 

n/a

1

(1.3%)

0

(0.0%)

Lung Cancer Information

Clinical Stage

IA

40

(50.6%)

54

(59.3%)

 

IB

9

(11.4%)

8

(8.8%)

 

IIA

6

(7.6%)

6

(6.6%)

 

IIB

5

(6.3%)

4

(4.4%)

 

IIIA

13

(16.5%)

14

(15.4%)

 

IIIB

2

(2.5%)

2

(2.2%)

 

IV

4

(5.1%)

3

(3.3%)

Pathology Stage

IA

38

(48.1%)

48

(52.7%)

 

IB

13

(16.5%)

18

(19.8%)

 

IIA

10

(12.7%)

15

(16.5%)

 

IIB

7

(8.9%)

3

(3.3%)

 

III

10

(12.7%)

6

(6.6%)

 

IV

1

(1.3%)

1

(1.1%)

Histology

Adenocarcinoma

61

(77.2%)

52

(57.1%)

 

Squamous Cell

8

(10.1%)

32

(35.2%)

 

Large Cell

1

(1.3%)

2

(2.2%)

 

Small Cell

2

(2.5%)

0

(0.0%)

 

Neuroendocrine

6

(7.6%)

1

(1.1%)

 

Mixed

1

(1.3%)

4

(4.4%)

The Meridian STS database had 117 past smokers who quit between one month and 62 years before surgery, but they were only eligible for screening if they quit15 or fewer years before. The distributions of both pack-years and quit-time differed significantly between the included and excluded patients (Table 2).

Table 2: Medians and Significance of Age, Pack-years, and Quit-time of Excluded and Included Patient Distributions.

Criteria

Excluded Median

(IRQ, n)

Included Median (IRQ,

n)

Significance

Age

72 (62-80, n=79)

67 (61-74, n=91)

p=0.051

Pack-years

25 (15-36, n=75)

50 (40-64, n=91)

p<0.001

Quit-time

(years)

22 (12-32, n=54)

2.5 (0.33-10, n=62)

p<0.001

Note: Age and pack-year criteria were for all patients (n=170), but quit-time only applied to past smokers (n=117). There were unavailable pack-year data for 4 patients and unavailable quit-time data for 1 patient.

Many excluded patients were up to 5 years younger or older than the required age range, but even more met the USPSTF age criteria and were excluded by pack-years or quit-time (Figure 1). Less than 20% fell outside the required range (Figure 2), so the high percentage of excluded patients must be more related to smoking history.

Figure 1: Age Distributions of Patients Included (n=91) and Excluded (n=75) by USPSTF Criteria.
Bars display percentage of patients who fall within each five-year interval. Of included patients, x ̅= 67.63 and s=7.33; of excluded patients, x ̅= 69.66 and s=11.52. The included patients between 80 and 85 years were both 80 years of age.

Figure 2: Percentage of All Patients Excluded by USPSTF Age, Pack-year, and Quit-time Criteria.
Age and pack-year criteria apply to all patients (n=170), but there was insufficient pack-year data for 4 patients. Quit-time only applies to past smokers (n=116). Bars also display 95% confidence intervals for the percentage of excluded patients by each variable.

Of all patients, approximately 25% smoked less than 30 pack years – a larger exclusion percentage than age (Figure 2). Over half of the excluded patients smoked for less than 30 pack-years: 34.6% between 15 and 29 pack-years and 20.5% for less than 15 pack-years (Figure 3).

Figure 3: Pack-year Distributions of Patients Included (n=91) and Excluded (n=79) by USPSTF Criteria.
Bars display percentage of patients who fall within each fifteen pack-year interval. Of included patients, x ̅= 57.68 and s=27.89; of excluded patients, x ̅= 28.07 and s=19.22. Four excluded patients had unavailable pack-year data and were excluded by age or quit-time.

Of past smokers excluded by USPSTF criteria, almost 75% had quit over 15 years prior to surgery (Figure 4). The remaining patients who did quit smoking within the past 15 years were disqualified by age, pack-years, or both. There were 116 past smokers in this study, and 37.9% (95% CI: 29.1-47.4%) had quit smoking more than 15 years before. A large percentage of excluded patients can be attributed to quit-time.

Figure 4: Quit-timed Distributions of Past Smokers Included (n=54) and Excluded (n=62) by USPSTF Criteria.
Bars display percentage of patients within each 5-year quit-time interval. Of included patients, x ̅= 4.71 and s=4.98; of excluded patients, x ̅= 23.07 and s=15.09. Current smokers (n=53) were omitted since they never quit. Quit time for 1 patient was unavailable.

There were 104 patients who met USPSTF criteria for pack-years (≥30) and quit-time (≤15 years), but 13 (12.5%, 95% CI: 6.8-20.4%) were excluded from screening due to age (Figure 5). There were also 13 patients (12.5%, 95% CI: 6.8-20.4%) included by age and quit-time criteria, but excluded by pack-years -- few were excluded solely by pack-years. Of past smokers between 55 and 80 years old who smoked over 30 pack-years, 23.9% (95% CI: 14.6-35.5%) were excluded by the quit-time criteria (Figure 5). This variable would have excluded more surgical lung cancer cases from screening than age and pack-years would have.

Figure 5: Percentage of Patients Excluded by Each USPSTF Criteria Variable Given Others Were Met.
One hundred and four patients met pack-year (≥30 pack-years) and quit time (≤15 years) criteria. There were 108 patients within the age range (55-80 years) and quit-time limit, but there was insufficient pack-year data for 4 of these patients. Quit-time only applies to the 116 past-smokers, of which 71 met age and pack-year criteria. Bars also display 95% confidence intervals for the percentage of excluded patients by each variable.

If each criterion was modified individually, an extension of quit time by 15 years would optimize the percentage of included patients. Patients in the study were within approximately 10 years of the USPSTF age range, but only about 5% more would have been included if the range was extended that many years (Figure 6). Reducing the pack-year criteria to 20 pack-years (10 pack-year reductions) would have included almost 60% of all patients, while disregarding the pack year criteria altogether would have included up to 61.2% (Figure 6). Since removing the pack-year criteria would expose light smokers to unnecessary radiation, smaller alterations in quit-time would be more reasonable. The percentage of Meridian patients included by USPSTF criteria increased to 59.4% when quit-time was set to 25 years (10 year extension) and 61.2% when extended to 30 years (Figure 6).

Figure 6: Percentage of All Patients (n=170) Included by USPSTF Criteria When Quit-time, Pack-year, and Age Criteria Were Extended.
Current guidelines include 53.5% of patients at 0 years of criteria extension. Each variable was extended by 5 years or pack-years until no more patients would have been included by that variable. The age range was extended below 55 years of age and then above 80 years of age.

However, since many patients would have been excluded by more than one variable, it is important to consider alterations in multiple variables. Pack-years and quit-time had significantly different distributions, as well as large exclusion percentages (Figure 7).

Figure 7: Patients (n, % of total) Excluded by Combinations of USPSTF Screening Criteria Variables. Totals of 29 excluded by age, 42 by pack years, and 44 by quit-time.

Although USPSTF criteria would have excluded almost half of Meridian cases, it fared better than NLST which would have excluded 58.8% (95% CI: 51.0-66.3%) of the same 170 cases. On the other hand, the NY-ELCAP would have only excluded 26.5% (95% CI: 20.0 34.8%), while the Mayo Clinic and European Institute of Oncology ELCAP sites would have only excluded 17.7% (95% CI: 12.2-24.2%) of the cases (Table 3). These sites had wider age ranges, lower pack year requirements, and no limit on quit-time.

Table 3: Percent of HMH Patients (n=170) Who Would Have Been Excluded by Past Criteria at Different ELCAP Sites.

ELCAP Program

Criteria

Excluded (%)

NY-ELCAP, NY [4]

≥60 years old

≥10 pack-years

26.47%

Mayo Clinic, Minnesota [5]

≥50 years old

≥20 pack-years

17.65%

European Institute of

Oncology, Milan [6]

≥50 years old

≥20 pack-years

17.65%

Physimed Medical Center,

Quebec [7]

≥45 years old

≥10 pack-years

7.65%

Sylvester Comprehensive

Cancer Center, Florida [8]

≥50 years old

≥10 pack-years

8.82%

University Health Network,

Toronto [9]

≥55 years old

≥10 pack-years

14.71%

International-ELCAP [14]

≥40 years old

>0 pack-years*

0.00%

Quit-time was unspecified for all sites. These past guidelines would have excluded fewer resectable lung cancer cases than current USPSTF guidelines. * I-ELCAP participants could also have been nonsmokers at risk due to secondhand or occupational exposure.

Discussion

Since most lung cancers are caused by heavy smoking, it is possible to detect them earlier by screening smokers at high risk. Past trials showed that low-dosage CT scans are most effective, but few studies have been conducted to determine the optimal population [4,10]. Current guidelines advise lung screening to past and present smokers who meet certain age and smoking history criteria. Almost half of the surgical lung cancer cases at Meridian Health would have been excluded by these guidelines.

National inclusion criteria specify age and pack-years of smoking, as well as quit-time for past smokers. According to our analysis, the criteria for age and pack-years would not have excluded as many HMH patients as quit-time. The data supports Yang et al.’s suggestion that the upper limit for quit-time be extended [14]. In fact, earlier studies did not have quit-time criteria, and would have excluded fewer patients. Based on our results, if a quit-time guideline must be set, we suggest extending it from 15 to 25 years.

Since some patients would have been excluded by more than one variable, there may be correlation between age, pack-years, and quit time. Alterations in one variable can affect another; for example, older age entails more time to have smoked or longer periods of cessation. As suggested by exclusion rates by ELCAP criteria, small adjustments in all variables can significantly change the percentage of excluded patients.

Cost effectiveness, accessibility, and insurance coverage must be considered to ensure that the benefits outweigh the costs and risks. Safety is also a priority since low-dose CT scans impose radiation danger on scanned subjects [15]. ELCAP sites would have detected a significantly higher percentage of patients than USPSTF recommendations, but also would have increased health risk to potential patients and financial cost to national programs. Further studies should investigate the financial costs and health risks of wider screening criteria.

Besides age and smoking history, other factors increase lung cancer risk. Prospective studies should inquire information on secondhand smoking, occupational risks, and prolonged exposure to air pollution [1]. Currently, nonsmokers are ineligible for screening, as well as those with history of cancer or prior CT scans, recent unexplained weight loss, or hemoptysis [10]. In the future, symptoms and medical history should be considered in data collection. Additionally, the data collected was at time of surgery, so past smokers who reported quitting less than a year before may have been current smokers at time of diagnosis. The Meridian sample is not a perfect reflection of all lung carcinomas, so a larger sample may yield more accurate results. Yet, if it is true, the national screening guideline is failing to detect lung cancer in high risk populations.

In conclusion, the study revealed that current USPSTF recommendations for lung screening fail to account for many lung cancer patients that can potentially be saved. We believe that the national criteria can be adjusted to detect cancer in high risk populations without unnecessary radiation exposure. From this analysis, we noted that past smokers who quit more than 15 years ago are still likely to develop lung cancer. Further studies should examine secondhand smoking and occupational exposure as risk factors, taking national cost and radiation danger into consideration.

Acknowledgements

Special thanks to Dr. Herbert Axelrod (1927-2017) for funding the Hackensack Meridian Health Scholars Research program at Jersey Shore University Medical Center. Dr. Axelrod generously donated funds to sponsor undergraduate research and mentorship during summers at Jersey Shore University Medical Center.

References

1. Sharma D, Newman TG, Aronow WS. Lung cancer screening: History, current perspectives, and future directions. Archives of Medical Science. 2015; 11: 1033.

2. Midthun DE. Early detection of lung cancer. F1000 Res. 2016.

3. International Early Lung Cancer Action Program. About I-ELCAP. Accessed July 24, 2017.

4. Henschke CI, Mc Cauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early lung cancer action project: A summary of the findings on baseline screening. Oncologist. 2001; 6: 147-152.

5. Swensen SJ, Jett JR, Hartman TE. CT screening for lung cancer: Five-year prospective experience. Radiology. 2005; 235: 259-265.

6. Pastorino U, Bellomi M, Landoni C. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. The Lancet. 2003; 362: 593-597.

7. Physimed Cancer Screening Center. Lung Cancer Screening. Accessed July 24, 2017.

8. Project focuses on early detection. Quest Magazine of the University of Miami Sylvester Comprehensive Cancer Center. 2006; 48.

9. University Health Network. Early Lung Cancer Screening. Accessed July 24, 2017.

10. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine. 2011; 365: 395-409.

11. USPSTF A and B recommendations. US Preventive Services Task Force Website.

12. Wang Y, Midthun DE, Wampfler JA, Deng B, Stoddard SM, Zhang S, et al. Trends in the proportion of lung cancer patients meeting screening criteria. JAMA. 2015; 313: 853-855.

13. Yang P, Wang Y, Wampfler JA, Xie D, Stoddard SM, She J, et al. Trends of high-risk subpopulations for lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2016; 11: 194-202.

14. The International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. The New England Journal of Medicine. 2006; 355: 1763-1771.

15. De Koning H, Meza R, Plevritis SK. Benefits and harms of CT lung cancer screening strategies. A comparative modeling study for the U.S. preventive services task force. Ann Intern Med. 2014; 160: 311-320.

Other Articles

Article Image 1

Merkel Cell Carcinoma of the Inguinal Lymph Node in the Absence of a Primary Site: A New Case Report and Literature Review

Introduction: Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. The main characteristics are frequent local recurrences and disseminations to regional lymph nodes and distant organs. MCC within the lymph nodes in the absence of a primary site is rare and few cases have been reported by the literature.

Case Report: We report a case of MCC presenting as a painless mass in the left inguinal area for 6 months in a 48-year-old women. The histopathology of the excised lesion revealed a poorly differentiated basophilic small cell tumor. The immunohistochemical study finding the diagnosis of a metastatic MCC. Despite extensive clinical and radiological investigation, we failed to identify the origin of the tumor.

Conclusion: Rare cases of MCC confined to a lymph node without an apparent primary site have been reported. We report a new case of MCC in the inguinal lymph node without identification of the primary site.

Mohamed Amine Azami¹, Othman Lahbali¹, Iliass El Alami², Zouidia F¹, and Mahassini N¹*


Article Image 1

Can be Seroma a normal event in Breast Surgery? Analysis from Survey in Plastic Surgery Safety Conference

Introduction: Breast Surgery especially augmentation is a common procedure worldwide. Literature reports relationship between chronic seroma and Anaplastic Large Cell Lymphoma (ALCL) has increased. Recently we reported the first case in Mexico. Risk factors should be evaluated. Seroma seems to be a common event after this type of surgery. Chronic seroma seems to be most common symptom in ALCL

Methods: Survey was conducted during Security Conference in breast implant augmentation, to know features as breast implants ratio in private practice of plastic surgeons, type of implant used, surgical technique and complications. Descriptive statistics including measures of central tendency were estimated.

Results: 72 members answered the survey. Implant placement is a procedure performed frequently. Preference is textured implants with volume between 300cc and 360cc. The most common complication was seroma. Reoperation was related with capsular contracture and patient no satisfaction.

Discussion: Seroma is a common complication. Possible relation with biofilm and Anaplastic Large Cell Lymphoma should be evaluated. Lymphoma is not a common finding in breast implant but long lasting infection can be considered as risk factor. Measures to prevent seroma should be proposed. Analysis from the type of textured in the coverage of the implant should be evaluated.

Conclusion: This information allows us to take further action to direct sessions, courses and conferences, to decrease the frequency of seroma and prevent complications being one of the procedures most frequently performed by the membership.

Guillermo Ramos-Gallardo¹,², Carlos-Guillermo Oaxaca-Escobar¹, Jesus Cuenca Pardo¹, Livia Contreras-Bulnes¹, Eugenio Rodríguez-Olivares³, Imelda Díaz-Ruiz⁴, and Mauricio Alejandro García-López⁴*


Article Image 1

Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors

Thyroglobulin levels ≥50 μg/L following thyroidectomy and I131 ablation correlate with poor prognosis in patients with high risk Differentiated Thyroid Cancer (DTC). We describe a case of a 54 year old woman with differentiated thyroid cancer and high thyroglobulin up to 220 μg/L following thyroidectomy and I131 ablation who demonstrated marked response to a novel immunotherapy involving autologous tumor cell transfected with a GMCSF/bi-shRNA furin expressive plasmid (Vigil). Activity is highlighted by four year disease free survival in correlation with immune activation as measured by ELISPOT assay of peripheral blood mononuclear cell reaction to autologous tumor. Further investigation with Vigil in differentiated thyroid cancer is warranted.

Minal Barve¹,², Radhika Barve¹, Jennifer Rao¹, Luisa Manning³, Donald D Rao⁴, Ned Adams¹, Neil Senzer¹,³,⁴ and John Nemunaitis¹-⁵*



Article Image 1

Role of Pre -Treatment FDG PET Quantitative Parameters in Prognostication of Head and Neck Squamous Cell Carcinoma - A Review

In spite of the good organ preservation strategies available for locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC), failure rates have been reported to be as high as 35-50%. There has been an increasing interest in predicting response to treatment, to aid early intervention and better outcomes. FDG-PET is a standard modality for post treatment evaluation, however it is still under utilized as a pre-treatment investigative modality. Several articles have described quantitative parameters in pre-treatment FDG-PET to prognosticate patients and determine likelihood of response to treatment however they are still not used commonly. This article was a review of the literature available on pre-treatment FDG PET quantitative parameters and their value in predicting failure. A thorough review of literature from MEDLINE and EMBASE was performed on pre treatment quantitative parameters in HNSCC. Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) were reliable parameters to predict response to organ preservation therapy, disease free and overall survival. SUVmax was an inconsistent parameter. MTV and TLG may help predict poor response to organ preservation to initiate early surgical salvage or modify therapeutic decisions to optimize clinical outcomes. Routine incorporation into PET reporting may provide additional information over SUVmax alone.

Narayana Subramaniam, Deepak Balasubramanian*, Shanmuga Sundaram P and Samskruthi Murthy 


Article Image 1

Staged Surgery Combined with Chemo Radiation Improves Outcome after Incomplete Removal of Gallbladder Cancer

Introduction: Gallbladder carcinoma is the most frequent tumor of the bile system and has a poor prognosis. The main proportion of tumors diagnosed coincidentally after gallbladder removal for various reasons. In these cases, an incomplete removal of the tumors occurs frequently. The adequate treatment of these patients is still under discussion. We present our experience with different procedures.

Patients and Methods: Between 1990 and 2015, we identified 20 patients which were presented at our University Hospital after incomplete removal of gallbladder cancer (R1, R2, RX) as incidental findings after cholecystectomy. The prospectively collected data including surgery, adjuvant treatment, histopathological examinations of the specimens and follow-up data were analyzed retrospectively.

Results: The median age of patients was 72 years (range 47-89 years), 90 % (18/20) were female. The median follow-up period was 10 months (range 0-109 months). The median survival of all patients was 11 months (95 % confidence interval: 5-17 months). The median survival of patients who received staged surgery and chemo radiation after incomplete gallbladder removal was significantly increased (median 32 months; range 4-109 months) vs. patients who received chemo radiation without surgery (median 13 months; range 8-51 months) or chemotherapy alone (median 2.5 months (range 0-40 months)) (p = 0.005).

Discussion: There is no standardized treatment for residual tumor after incomplete gallbladder cancer resection. Our data demonstrate that staged surgery with prior chemo radiation may improve patient´s outcome. Surgery can be performed with low morbidity and mortality.

Marc Daniels¹, Maximilian Brunner¹, Sabine Semrau², Robert Grützmann¹ and Roland S Croner¹*


Article Image 1

Limb Salvage in Patients with Unresectable Recurrent Melanoma and Sarcoma with the Hyperthermic Isolated Limb Perfusion Technique

Introduction: Hyperthermic Isolated Limb Perfusion (HILP) is a surgical procedure for the regional delivery of heat and high doses of chemotherapy and biologic agents to the extremity. The procedure is employed as a limb salvage technique for locally advanced primary malignancies or recurrent cancers that are unresectable and confined to the extremity

Methods: From 1987-2016, 247 patients with unresectable recurrent melanoma (95%), sarcoma or Merkel Cell Carcinoma underwent HILP for limb salvage of the affected extremity after staging was negative for Stage IV disease and disease was confirmed to be confined to the extremity.

Results: All patients had limb salvage with this protocol. All patients were clinically negative in their regional basin at the time of perfusion, although 40% of the patients had evidence of regional nodal disease following nodal dissections. Immediate responses (within 3 months) on the extremity to the HILP were as follows: complete response (CR) of 66%, partial response (PR) of 20%, 10% stable disease and 4% progressive disease. With a mean follow-up period of 5 years, 61.5% of the patients have recurred with 68.4% of the recurrences being systemic, 21% regional nodal, 7.2% in-transit and 3.3% local-regional soft tissue.

Conclusions: HILP is an effective strategy for limb salvage in patients with unresectable, locally advanced cancers confined to the extremity. The treatment was associated with a high rate of complete responses on the extremity. Most patients recurred with distant metastases emphasizing the need for better systemic therapies for these malignancies.

Synopsis: Patients with recurrent, unresectable melanoma, other cutaneous malignancies and sarcoma confined to an extremity are problematic for clinicians since recurrence rates show that most will have occult systemic disease. An aggressive amputation approach does not make sense and the fact that these patients have active disease makes them ineligible for approved adjuvant therapies. In addition since their clinically apparent active disease is confined to the local/regional soft tissues making them Stage 3 disease, they are not eligible for Stage IV protocols. In these situations Hyperthermic Isolated Limb Perfusion (HILP) effectively treats the extremity with high response rates and a 100% limb salvage rate.

Lauren Kerivan, Michael Reintgen, Eric Reintgen, Steve Shivers and Douglas Reintgen* 


Article Image 1

Self-related Quality of Life and Functional Results after Internal and External Hemipelvectomy in 82 Musculoskeletal Pelvic Tumours

Background and purpose: Wide resection in pelvis delivers important drawbacks not only physically but also mentally lowering the functional status and self-related quality of life (SRQL) of these patients. Our aim is to show functional results and SRQL in patients with wide resections in pelvis due to musculoskeletal tumours.

Patients and Methods: It is a retrospective study in patients with wide resections in pelvis due to musculoskeletal tumours and we focus on: demographical data, preoperative and pathology studies, type of resection and reconstruction, functional results (MSTS score) and SRQL (SF-12). We have performed 15 external hemipelvectomies (EH), 57 internal hemipelvectomies with pelvic ring stability reconstruction (IHPR), 10 internal hemipelvectomies without reconstruction of the pelvic stability (IHWR). There were 10 patients with soft tissue sarcomas and benign but aggressive tumours that we do not include in the study as they did not need hemipelvectomy.

Results: We found there is a tendency to better functional results in IHPR, though it shows no statistical differences between the three types of reconstruction. According to SRQL we observed light score loss in mental status related to general population. On the other hand, physical status showed strong score deviation from general population. Functional results seem to be similar to literature.

Interpretation: The severe loss of function and physical status in these patients underline the type reconstruction and avoiding complications as critical steps. The light score deviation in mental status may represent an adaptive pattern and social support of patients with this severe disease and its complications.

Pérez-Muñoz Israel*


Article Image 1

Alveolar Soft Part Sarcoma: Case Report of a Rare Tumor and Review of Literature

Alveolar soft part sarcoma (ASPS) is a rare neoplasm occurring most frequently in the soft tissues of both children and adults, which has a tendency for an indolent course and late metastasis. It is characterized by an unbalanced translocation, der(17)t(X:17)(p11;p25), producing a fusion protein which has recently been shown to play a role in promoting cell proliferation and angiogenesis and may provide a potential target for molecular therapy. We present a case of ASPS and discuss the histology, diagnostic considerations, cytogenetics, treatment, and prognosis.

Glyn Hinnenkamp*, Amy Hackett, Brandon Grodman, Logan Primeaux , Ashley Green, Savannah Sadaiappen , Sylvester Bote, and Mohamed Aziz 


Article Image 1

Secondary primary common bile duct neuroendocrine tumor 10 years after the diagnosis of rectal adenocarcinoma: A case report

Development of a second primary cancer in patients under follow-up because of metastasis is rare. We presented a 58-year-old man with neuroendocrine cancer of vater ampulla and distal common bile duct as a second primary cancer. The patient had been diagnosed with rectal adenocarcinoma and lung metastasis who underwent total mesorectal excision, lung lobectomy, and adjuvant therapy with an interval of 5 years. This article emphasizes on the importance of early detection of second primary cancer and treating it as the primary one

Saba Ebrahimian MD, Sakineh Soleimani Varaki MD 


Article Image 1

Metastatic Chordoma to the lung. Case Report of a Rare Tumor and Brief Review of the Literature

Chordomas are rare, malignant bone tumors with a typically unfavorable prognosis that develop slowly and aggressively along the skull base and axial skeleton from remnants of the primitive notochord. Grossly, chordomas classically present as lobular nodules with thick fibrous tissue; histologically, those fibrous tissues can be seen separating chords of tumor cells in a myxoid stroma. Its characteristic local aggressiveness and indolent growth makes timely detection difficult and local recurrence likely, especially since surgical resection and radiation are the only affective treatment options. Local recurrence currently serves as a significant predictor of metastatic progression which most commonly involves the lungs, liver, bone, and lymph nodes. We report a case of metastatic chordoma to the lung, and discuss the diagnostic features, differential diagnosis, molecular changes, treatment, and prognosis.

Bryan Neal*, Sidney Nathan, Adam Hebert, Clifford Davis, Jodie Simelda, Anthony Dean, Gevork Seifert, Mohamed Aziz